One To Watch
Myellama
Company Overview
A Canadian pre-clinical biotechnology company developing tri-specific NK cell and T cell engagers targeting TACI and BCMA for the treatment of multiple myeloma, with first patient enrollment targeted for 2027. Myellama's lead program draws on next-generation NK cell engager technology licensed from the National Research Council Canada. The company is building toward simultaneous regulatory filings with Health Canada and US authorities to support its first-in-human trial.
Headquarters and Global Presence
Myellama is a Canadian biotechnology company. Its August 2026 strategic partnership with South Korean firm Vaxcellbio signals an early ambition to develop its programs across North American and Asian markets simultaneously.
Founding and History
Myellama is a pre-clinical stage company whose technology base is grounded in the National Research Council Canada's NK cell engager research program. The company is currently completing a funding round intended to advance its lead program through regulatory filings and into the clinic.
Therapy Areas and Focus
Myellama is focused exclusively on multiple myeloma, a plasma cell malignancy that remains incurable despite a proliferation of approved therapies including proteasome inhibitors, immunomodulatory drugs, and BCMA-directed agents. The unmet need in relapsed/refractory disease is substantial: patients who progress after BCMA-targeting CAR-T or antibody-drug conjugates have few options. Myellama's angle is that redirecting innate NK cell killing, rather than relying solely on T cell mechanisms, may offer a complementary or combinable approach.
Technology Platforms and Modalities
The company's core modality is the tri-specific engager, a single molecule designed to simultaneously engage an immune effector cell and two tumor-associated antigens. Myellama's constructs target both TACI and BCMA on myeloma cells while activating NK cells or T cells. The dual-antigen targeting strategy is a deliberate response to antigen escape, a recognized mechanism by which myeloma evades single-target BCMA therapies. The National Research Council Canada's next-generation NK cell engager platform underpins the molecular design.
Key Pipeline and Programs
Myellama's lead program is a tri-specific NK cell engager targeting TACI and BCMA, the two most clinically validated surface antigens in multiple myeloma. BCMA is the antigen class underlying approved therapies including belantamab mafodotin, idecabtagene vicleucel, and teclistamab; adding TACI co-targeting is intended to reduce the likelihood of antigen-loss relapse. A parallel tri-specific T cell engager format targeting the same TACI/BCMA pair broadens the mechanistic options within the same antigen strategy. Both programs are pre-clinical, with no trial registration numbers yet available. The company has stated it expects to file clinical trial applications with Health Canada and the US regulator concurrently, targeting first patient enrollment in 2027.
Recent Developments
On 4 August 2026, Myellama signed a strategic memorandum of understanding with South Korean immune-oncology company Vaxcellbio to jointly develop a novel multiple myeloma therapy based on the National Research Council Canada's NK cell engager technology. The MOU is the company's first disclosed international co-development agreement. Myellama has also stated it is completing a funding round to support its dual regulatory filing strategy ahead of the planned 2027 trial start.
Key Personnel
Specific executive names have not been disclosed in available sources.
Strategic Partnerships
Myellama's most significant disclosed relationship is a strategic MOU with Vaxcellbio, a South Korean immune-oncology company, signed 4 August 2026, covering joint development of the TACI/BCMA NK cell engager program. The technology underlying the program originates from the National Research Council Canada, which represents a foundational institutional relationship for the company.
FAQ Section
Single-antigen BCMA therapies, including approved CAR-T products and bispecific antibodies, face a documented resistance mechanism: myeloma cells can downregulate or shed BCMA, causing relapse. By co-targeting TACI, a second antigen expressed on plasma cells and malignant myeloma cells, Myellama's tri-specific format aims to force the tumor to lose two antigens at once to escape, which is substantially harder. The strategy is mechanistically similar to combination antigen targeting in CAR-T design, but delivered as a single off-the-shelf molecule.
NK cells are innate immune effectors that kill targets without requiring prior antigen sensitization, and myeloma cells express activating ligands for NK receptors. NK cell engagers redirect this existing cytotoxicity toward defined tumor antigens without the manufacturing complexity of autologous CAR-T therapy. The approach can in principle function as an off-the-shelf product, which is a key practical advantage over patient-derived cell therapies in a disease population that is often heavily pre-treated and immunocompromised.
Approved bispecific T cell engagers in myeloma, such as teclistamab, bridge a single tumor antigen to a T cell receptor component. Myellama's tri-specific format engages two tumor antigens and one immune effector receptor in a single molecule, increasing valency without requiring combination dosing. The NK cell engager variant activates a different effector population entirely, which may be relevant in patients whose T cell compartment is depleted by prior therapies or stem cell transplantation.
The TACI/BCMA NK cell engager program is pre-clinical. Myellama has stated it is completing a funding round to enable simultaneous clinical trial applications to Health Canada and US regulators, with first patient enrollment targeted for 2027. No trial registration numbers have been published yet, and the program has not yet entered the investigational new drug application process publicly.
The August 2026 MOU with Vaxcellbio brings a South Korean immune-oncology partner into the co-development of the NK cell engager program, extending Myellama's potential geographic reach beyond North America at an early stage. Vaxcellbio's focus on immuno-oncology is aligned with the NK cell engager approach. As an MOU, the arrangement is a framework for collaboration rather than a concluded licensing or funding transaction, so the operational terms remain to be formalized.
Myellama's disclosed pipeline is focused entirely on multiple myeloma, a hematologic malignancy of plasma cells. The TACI/BCMA family covers both NK cell engager and T cell engager formats within the same disease, giving the company two mechanistic routes to the same indication rather than breadth across tumor types. This concentrated focus is consistent with a pre-clinical company prioritizing depth of proof-of-concept in a single indication before expanding.
The principal watchpoints for Myellama over the next 18 months include:
- Completion of the current funding round, which gates the simultaneous Health Canada and US regulatory filings.
- Publication or presentation of pre-clinical data for the TACI/BCMA NK cell engager to substantiate the dual-antigen rationale.
- Progression of the Vaxcellbio MOU into a binding co-development or licensing agreement.
- First patient enrollment in 2027 as the pivotal near-term clinical milestone.
- Competitive pressure from an already crowded BCMA-targeting field, including approved bispecifics and CAR-T products from major pharma, which raises the bar for differentiation on both efficacy and safety.
Today's issue
| Headless Content Management with Blaze